Trials / Terminated
TerminatedNCT05154630
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
Phase I Clinical Trial Evaluating the Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancies
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is divided into two phases: dose escalation and cohort expansion. The dose escalation stage aims to evaluate the tolerability, pharmacokinetic characteristics and safety of TQB2858 injection in subjects with advanced malignant tumors. The cohort expansion phase aims to evaluate the initial efficacy and safety of TQB2858 injection in patients with soft tissue sarcoma, and to explore treatment-related biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2858 injection | TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody. |
Timeline
- Start date
- 2022-01-14
- Primary completion
- 2023-03-31
- Completion
- 2023-06-30
- First posted
- 2021-12-13
- Last updated
- 2024-01-18
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05154630. Inclusion in this directory is not an endorsement.